

TAKAFULINK DANA ESG GLOBAL


All information as at 31 October 2025 unless otherwise stated
Semua maklumat adalah seperti pada 31 Oktober 2025 melainkan jika dinyatakan

Objective / Objektif Dana

Takafulink Dana ESG Global aims to maximise returns over long term by investing in a qualified Sustainable and Responsible Investment (SRI) Fund.

Takafulink Dana ESG Global bertujuan untuk memaksimumkan pulangan jangka masa panjang dengan melabur dalam Dana Pelaburan Mampan dan Bertanggungjawab (SRI) yang berkelayakan.

Where the Fund invests Komposisi Pelaburan Dana



Asset Allocation Peruntukan Aset


	% NAV
1 Nomura Global Shariah Sustainable Equity Fund	100.44
2 Cash, Deposits & Others	-0.44

Fund Details / Maklumat Terperinci Dana

Investment Manager / Pengurus Pelaburan	Prudential BSN Takaful Berhad
Inception Date / Tarikh Diterbitkan	20/03/2023
Current Fund Size / Saiz Dana Terkini	RM14,383,847.11
Annual Fund Management Charge / Caj Pengurusan Dana Tahunan	1.50% per annum
Current NAV / NAB Terkini	RM1.40607

How the Fund has performed / Prestasi Dana

Performance Graph / Jaduan Prestasi Dana
Takafulink Dana ESG Global Vs. Dow Jones Islamic Market
Developed Markets Index



Total Price Movement Over the Following Periods / Jumlah Pergerakan Harga Dalam Tempoh Tersebut

	1 month	3 months	6 months	1 year	3 years	5 years	Since Inception
Price Movement / Pergerakan Harga	4.49%	8.04%	19.26%	9.07%	NA	NA	40.61%
Benchmark / Penanda Aras	3.49%	8.37%	22.63%	16.54%	NA	NA	52.93%
Outperformance / Perbezaan Prestasi	1.00%	-0.33%	-3.37%	-7.47%	NA	NA	-12.32%

TAKAFULINK DANA ESG GLOBAL

All information as at 31 October 2025 unless otherwise stated

Semua maklumat adalah seperti pada 31 Oktober 2025 melainkan jika dinyatakan

Monthly Update / Laporan Bulanan Terkini

Fund Review & Strategy

The Fund returned 4.49% for the month, outperforming the benchmark return of 3.49% by 1.00%. Year-to-date, The Fund returned 9.93%, underperforming the benchmark return of 11.60% by 1.67%. After 9 months since the last rate cut, US Federal Reserve has announced another rate cut while unveiling hints on more rate cuts in the next two FOMC meetings which is in-line with market expectations. Bank of Japan on the other hand remains to be patient with no rate hike announcement in-line with expectation while investors look forward for the new Prime Minister election within the LDP party. Apart from macro updates, major semiconductor announcements have dominated the month where Nvidia invested in OpenAI, Nvidia invested in Intel to jointly develop PC and DC chips, Broadcom secured \$10B deal with OpenAI, US government invested in Intel as well as Intel attempted to seek investment from Apple. While there is no change in Intel's capability overnight with TSMC remains the chip manufacturing leadership, sentiment has improved dramatically where market expects fresh fund for Intel would boost semiconductor production equipment (SPE) spending. Towards the end of the month, Pfizer announced an unexpected drug pricing deal with the president Trump where Pfizer agreed to have all its Medicaid drugs and new medications to be priced at Most Favored Nation level, all drugs to be available to direct to cash paying patients as well as to invest \$70B in the US in exchange of tariff exemption. Investors received the drug pricing deal news positively with as more improvements and policy certainties are anticipated. In September, MYR Class A delivered +3.43% slightly underperforming the benchmark by 16bps. By region, NA market delivered top performance with APAC market being second followed by EU market. While the fund gained strong outperformance in the EU market, it was mostly offset by underperformance from sector allocation in the NA market. Despite holding low cash level, there was some cash drag given strong positive market performance. By sector, strong selections in IT and Communication Services were offset by Healthcare and Financials.

The top contributors to the relative performance were Alphabet and Taiwan Semiconductor Manufacturing. Target Fund Manager's high conviction in Alphabet as an undervalued asset has rewarded well when DoJ's final rule exclude the worst outcome of forced divestment. On the other hand, the bottom contributors to the relative performance were Boston Scientific and AstraZeneca. They suspect that Boston Scientific underperformance would be short-term given Medtech industry is used as source of fund for other higher growth industries. On the bright side, Target Fund Manager is encouraged to see Boston Scientific mid-term plan announcement. The Company guided annual revenue growth of over +10% (up from previous range of +8%-10%) and margin expansion of 50bps per annum which in combination to continue supporting a strong double-digit EPS growth through 2028. They believe they are achievable given Company's rich product innovation lineup. Underweight in Tesla was also atop detractor, but they believe that the performance of the overvalued assets would be less sustainable.

Tinjauan dan Strategi Dana

Dana menjana pulangan 4.49% pada bulan ini, mengatasi pulangan penanda aras 3.49% dengan perbezaan 1.00%. Sejak awal tahun sehingga kini, Dana menghasilkan pulangan 9.93%, tidak mengatasi pulangan penanda aras 11.60% dengan perbezaan 1.67%. Selepas 9 bulan sejak pemotongan kadar terakhir, Rizab Persekutuan AS mengumumkan satu lagi pemotongan kadar sambil mendedahkan petunjuk tentang lebih banyak pemotongan kadar dalam dua mesyuarat FOMC yang akan datang, selaras dengan jangkaan pasaran. Sebaliknya, Bank of Japan masih bertahan dengan tiada pengumuman kenaikan kadar, selaras dengan jangkaan, sementara pelabur menantikan pilihan raya Perdana Menteri baharu dalam parti LDP. Selain daripada kemas kini makro, pengumuman semikonduktor utama telah mendominasi bulan tinjauan yang mana Nvidia melabur dalam OpenAI, Nvidia melabur dalam Intel untuk membangunkan cip PC dan DC bersama-sama, Broadcom memperoleh perjanjian USD10 bilion dengan OpenAI, kerajaan AS melabur dalam Intel manakala Intel cuba mendapatkan pelaburan daripada Apple. Sungguhpun keupayaan Intel tidak berubah semalaman dengan TSMC kekal sebagai peneraju pembuatan cip, namun sentimen naik mendadak yang mana pasaran menjangkakan dana baharu buat Intel akan menambah perbelanjaan peralatan pengeluaran semikonduktor (SPE). Menjelang akhir bulan, Pfizer mengumumkan perjanjian luar jangkaan harga ubat dengan presiden Trump yang mana Pfizer bersetuju untuk menetapkan harga pada peringkat Negara Paling Digemari, lalu semua ubat akan tersedia secara langsung buat pesakit yang membayar secara tunai serta melabur USD70 bilion di AS sebagai pertukaran kepada pengecualian tarif. Pelabur menyambut berita perjanjian harga ubat secara positif dengan lebih banyak penambahbaikan dan kepastian dasar dijangkakan. Pada bulan September, MYR Kelas A mencatatkan +3.43%, tidak mengatasi pencapaian penanda aras dengan kekurangan sekecil 16 mata asas. Berdasarkan rantau, pasaran NA mencatatkan prestasi terbaik dengan pasaran APAC berada di tempat kedua diikuti oleh pasaran EU. Walaupun Dana meraih prestasi yang lebih baik dalam pasaran EU, namun sebahagiannya ditimbal oleh prestasi hambar daripada peruntukan sektor dalam pasaran NA. Meskipun pegangan paras tunai rendah, terdapat sedikit seretan tunai memandangkan prestasi pasaran yang positif lagi mantap. Berdasarkan sektor, pilihan kukuh dalam Perkhidmatan IT dan Komunikasi ditimbal oleh Penjagaan Kesihatan dan Kewangan. Penyumbang utama kepada prestasi relatif ialah Alphabet dan Taiwan Semiconductor Manufacturing. Keyakinan tinggi Pengurus Dana Sasaran terhadap Alphabet sebagai aset dinilai rendah telah memberi ganjaran yang baik apabila peraturan akhir DoJ mengecualikan hasil terburuk daripada pemberhentian pelaburan (divestment) secara paksa. Sebaliknya, penyumbang terendah kepada prestasi relatif ialah Boston Scientific dan AstraZeneca. Mereka mengesyaki bahawa prestasi rendah Boston Scientific bersifat jangka pendek memandangkan industri Medtech digunakan sebagai sumber dana buat industri pertumbuhan tinggi yang lain. Dari sudut yang cerah, Pengurus Dana Sasaran digalakkan untuk melihat pengumuman pelan pertengahan penggal Boston Scientific. Syarikat ini membimbing pertumbuhan pendapatan tahunan lebih +10% (meningkat daripada julat sebelumnya +8%-10%) dan pengembangan margin sebanyak 50 mata asas setahun yang bila digabungkan akan terus menyokong pertumbuhan dua digit EPS yang kukuh sehingga 2028. Pengurus percaya bahawa pertumbuhan ini boleh dicapai memandangkan kekayaan pelbagai produk berinovasi Syarikat tersebut. Kekurangan pegangan dalam Tesla juga merupakan penggugat prestasi utama, tetapi pengurus percaya bahawa prestasi aset yang terlebih nilai tidak begitu mampan.

Source / Sumber: Fund Commentary, October 2025, Nomura Asset Management Malaysia Sdn. Bhd.

Disclaimer

Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units may fall as well as rise. Past performances of the funds and that of the fund managers are not necessarily indicative of future performance. The price movements indicated are not reflective of the actual return on your investments (which are subject to your premium allocation rate and deduction charges). The actual return on your invested premiums may fluctuate based on the underlying performance of the investment-linked funds. All Takafulink Dana are invested in Shariah-approved securities and/or Islamic private debt securities. This leaflet is for illustrative purposes only. For further details on the terms and conditions, please refer to the policy document. For further details on how you can invest in these funds, please refer to the respective product brochures. In the event of discrepancy between the information in this fact sheet and the policy document, the information in the policy document shall prevail.

Pelaburan adalah tertakluk kepada risiko-risiko pelaburan termasuk kemungkinan kehilangan jumlah wang pokok yang dilabur. Nilai unit mungkin naik ataupun jatuh. Prestasi masa dulu dana-dana atau pengurus-pengurus dana tidak semestinya mencerminkan prestasi masa depan. Pergerakan harga yang ditunjukkan tidak menggambarkan pulangan sebenar pelaburan anda (yang tertakluk kepada kadar peruntukan premium dan caj potongan). Pulangan sebenar ke atas premium yang anda labur mungkin berbeza, bergantung kepada prestasi dana-dana). Semua Takafulink Dana dilaburkan dalam sekuriti yang diluluskan oleh Syariah dan/atau sekuriti hutang swasta Islam. Risalah ini disediakan hanya untuk gambaran semata-mata. Sila rujuk kepada dokumen polisi untuk keterangan lanjut mengenai terma-terma dan syarat-syarat. Untuk keterangan lanjut mengenai bagaimana anda boleh melabur dalam dana-dana ini, sila rujuk kepada risalah-risalah produk yang berkenaan. Jika terdapat perbezaan di antara helaian fakta dan dokumen polisi, maklumat dalam dokumen polisi dianggap muktamad.

TAKAFULINK DANA ESG GLOBAL

All information as at 31 October 2025 unless otherwise stated

Semua maklumat adalah seperti pada 31 Oktober 2025 melainkan jika dinyatakan

PRUDENTIAL BSN

TAKAFUL